Compound: Repaglinide
SMILES: O=C(O)c1c(OCC)cc(CC(=O)N[C@H](c2c(N3CCCCC3)cccc2)CC(C)C)cc1
InChIKey: FAEKWTJYAYMJKF-QHCPKHFHSA-N
Synonyms: Repaglinide, 135062-02-1, Prandin, GlucoNorm, Repaglinida, AG-EE 623 ZW, Repaglinidum, AG-EE 388 ZW, AGEE-623ZW, AG-EE-623ZW, NSC-759893, AG-EE-623-ZW, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid, DTXSID3023552, A10BX02, 668Z8C33LU, DTXCID603552, (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid, 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid, Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-, enyglid, repa-glinide, 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid, AG-EE 388, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid, (+)-repaglinide, 2-ethoxy-4-((((1S)-3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)carbamoyl)methyl)benzoic acid, 2-ethoxy-4-(2-(((1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl)amino)-2-oxoethyl)benzoic acid, RefChem:56406, 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid, (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, 629-921-1, Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-, 2-ethoxy-4-(2-(((1R)-3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid, repaglinide impurity E, NovoNorm, (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid, Repaglinidum [INN-Latin], Repaglinida [INN-Spanish], C27H36N2O4, MFCD00906179, AG-EE 623ZW, (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid, CHEMBL1272, (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid, (S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid, 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid, NCGC00016978-01, Repaglinide [USAN], CAS-135062-02-1, Actulin, Surepost, (-)-Repaglinide, Reglin, (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid, (S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid, SMR000466305, Prandin (TN), Repaglinide (JAN/USP/INN), UNII-668Z8C33LU, AG-EE-623 ZW, Novonorm;, Repaglinide CRS, AG-EE-388, SMP-508, Surepost (TN), BJX, Repaglinide [USAN:USP:INN:BAN], NN-623, Repaglinide (Standard), 111GE012, REPAGLINIDE [MI], Prestwick0_001046, Prestwick1_001046, Prestwick2_001046, Prestwick3_001046, REPAGLINIDE [INN], REPAGLINIDE [JAN], REPAGLINIDE [VANDF], (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid, REPAGLINIDE [MART.], SCHEMBL16137, BSPBio_000972, REPAGLINIDE [USP-RS], REPAGLINIDE [WHO-DD], MLS000759407, MLS001076684, MLS001424111, MLS006011560, BIDD:GT0338, SPBio_002906, REPAGLINIDE [EMA EPAR], BPBio1_001070, CHEBI:8805, GTPL6841, orb1309813, Repaglinide - Bio-X trade mark, SCHEMBL29373506, SCHEMBL29392295, AG-EE-623, MSK7195, REPAGLINIDE [ORANGE BOOK], Repaglinide for system suitability, GLXC-05202, HMS1571A14, HMS2051N08, HMS2094C07, HMS2098A14, HMS2231M21, HMS3414D09, HMS3678D09, HMS3715A14, Pharmakon1600-01506035, REPAGLINIDE [EP MONOGRAPH], REPAGLINIDE [USP MONOGRAPH], Tox21_110721, AC-726, BDBM50153520, EBC-06064, HB1106, HY-15209R, MSK7195-100A, NSC759893, s1426, STK629501, AKOS005561792, MSK7195-1000A, Repaglinide for system suitability CRS, Repaglinide, >=98% (HPLC), solid, BS-1010, CCG-101013, CS-0979, DB00912, FR27699, NC00263, NSC 759893, NCGC00016978-02, NCGC00016978-04, NCGC00016978-05, NCGC00016978-15, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxo-ethyl]benzoic acid, BR164332, HY-15209, SY046828, SBI-0206942.P001, AB00514019, R0179, SW197344-4, C07670, D00594, F15001, Repaglinide Solution in Acetonitrile, 100ug/mL, AB00514019-09, AB00514019_10, AB00514019_11, Repaglinide Solution in Acetonitrile, 1000ug/mL, SR-01000759404, Q2195995, SR-01000759404-4, BRD-K82846253-001-03-0, BRD-K82846253-001-14-7, BRD-K82846253-001-15-4, BRD-K82846253-001-16-2, Z1501485370, Repaglinide, European Pharmacopoeia (EP) Reference Standard, Repaglinide, United States Pharmacopeia (USP) Reference Standard, (s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid, Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard, (+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID, (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid, (S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID, (S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid, 2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid
Theoretical properties:
molecular_formula: C27H36N2O4
molecular_weight: 452.6 g/mol
exact_mass: 452.26750763 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 10
heavy_atom_count: 33
topological_polar_surface_area: 78.9 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 130-131 °C
solubility: 2.94e-03 g/L
Descriptions:
pubchem: Repaglinide is a member of piperidines.
chembl: REPAGLINIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.